{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-016968","form_type":"8-K","ticker":null,"cik":"0001178879","company_name":"AMICUS THERAPEUTICS, INC.","filed_at":"2026-04-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.039130+00:00","generated_at":"2026-05-15T03:44:44.078582+00:00","sec_items":["1.02","2.01","3.01","3.03","5.01","5.02","5.03","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Amicus Therapeutics acquired by BioMarin for $14.50 per share in all-cash merger","bullets":["Merger completed on April 27, 2026; Amicus shareholders receive $14.50 per share in cash.","Company Common Stock will be suspended from trading on Nasdaq effective April 28, 2026.","All outstanding equity awards were cancelled and converted into cash payments based on the merger consideration.","Entire board of directors and executive officers resigned; new directors and officers from BioMarin appointed.","Amicus repaid and terminated its October 2023 loan agreement with Blackstone and other lenders."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-016968","json":"https://secwatch.observer/filing/0001140361-26-016968.json","markdown":"https://secwatch.observer/filing/0001140361-26-016968.md","text":"https://secwatch.observer/filing/0001140361-26-016968.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178879/000114036126016968/0001140361-26-016968-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178879/000114036126016968/ef20071351_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T03:44:44.078582+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"793dc0e84ddd7af3063300ff324ee04f9593d70b","claim":"AMICUS THERAPEUTICS, INC.: Amended and restated bylaws in their entirety to conform to Merger Sub's bylaws.","evidence_excerpt":"In addition, pursuant to the terms of the Merger Agreement, as of the Effective Time, the Company’s bylaws, as in effect immediately prior to the Effective Time, were amended and restated in their entirety to conform to the bylaws of Merger Sub as in effect immediately prior to the Effective Time, except that references to Merger Sub’s name were replaced by references to the name of the Surviving Corporation (the “ Amended and Restated Bylaws ”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178879/000114036126016968/0001140361-26-016968-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"}],"fact_type":"governance_change"},{"claim_id":"bbaa5bf161ff2e49eb7e67b5c01ab185144cd526","claim":"AMICUS THERAPEUTICS, INC.: Amended and restated certificate of incorporation in its entirety.","evidence_excerpt":"Pursuant to the terms of the Merger Agreement, as of the Effective Time, the Company’s certificate of incorporation, as in effect immediately prior to the Effective Time, was amended and restated in its entirety to be in the form of Annex I to the Merger Agreement (the “ Amended and Restated Certificate of Incorporation ”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178879/000114036126016968/0001140361-26-016968-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"}],"fact_type":"governance_change"},{"claim_id":"0e06bfbcd6d2c763a43e115fcf54dd76d45d98c0","claim":"AMICUS THERAPEUTICS, INC. underwent a change of control involving BioMarin Pharmaceutical Inc. for $14.50 per Share, in cash (closed 2026-04-27).","evidence_excerpt":"”), issued and outstanding immediately prior to the Effective Time (other than Excluded Shares and Dissenting Shares) was cancelled and converted into the right to receive $14.50 per Share, in cash, without interest thereon (the “ Merger Consideration ”) and subject to any applicable withholdings of Taxes. Pursuant to the Merger Agreement: • At the","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178879/000114036126016968/0001140361-26-016968-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"BioMarin Pharmaceutical Inc."},{"label":"Consideration","value":"$14.50 per Share, in cash"},{"label":"Closing","value":"2026-04-27"}],"fact_type":"ma_transaction"},{"claim_id":"013f368c9cc032b1c2792de29362e0d3c1e38703","claim":"AMICUS THERAPEUTICS, INC. terminated Amicus Credit Agreement (effective 2026-04-27).","evidence_excerpt":"On April 27, 2026, in connection with the Merger, the Company repaid in full all outstanding indebtedness and all other amounts due and payable and terminated all commitments under that certain Loan Agreement, dated October 2, 2023, (as amended, restated, amended and restated, supplemented and otherwise modified from time to time prior to the Closing Date, the “ Amicus Credit Agreement ”), by and among the Company, each of its subsidiaries party thereto, as guarantors, Blackstone Alternative Credit Advisors LP, Blackstone Life Sciences Advisors L.L.C., certain lenders from time to time party thereto and Wilmington Trust, National Association, as agent for the lenders.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178879/000114036126016968/0001140361-26-016968-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"credit facility"},{"label":"Effective","value":"2026-04-27"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}